Verastem Oncology Doses First Patient in TARGET-D 203 Trial
BOSTON, July 28, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 203 Phase...
Verastem Oncology
Advertisement
Verastem Oncology Doses First Patient in Phase 2 VS-7375 NSCLC Trial
BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...
Verastem Oncology Shows Encouraging Survival Data in RAMP 205 Pancreatic Cancer Trial
BOSTON, June 17, 2026 Verastem Oncology announced positive updated safety and efficacy findings from the Phase 1b/2a RAMP 205...
Verastem Oncology Doses First Patient in TARGET-D 201 Trial
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
Advertisement
